Kette, S.; Reccardini, N.; Salton, F.; Confalonieri, P.; Andrisano, A.; Chianese, M.; De Nes, A.; Maggisano, M.; Galantino, A.; Nicolosi, S.;
et al. The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis. Pharmaceuticals 2025, 18, 411.
https://doi.org/10.3390/ph18030411
AMA Style
Kette S, Reccardini N, Salton F, Confalonieri P, Andrisano A, Chianese M, De Nes A, Maggisano M, Galantino A, Nicolosi S,
et al. The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis. Pharmaceuticals. 2025; 18(3):411.
https://doi.org/10.3390/ph18030411
Chicago/Turabian Style
Kette, Stefano, Nicolò Reccardini, Francesco Salton, Paola Confalonieri, Alessia Andrisano, Maria Chianese, Anna De Nes, Marta Maggisano, Alessandra Galantino, Salvatore Nicolosi,
and et al. 2025. "The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis" Pharmaceuticals 18, no. 3: 411.
https://doi.org/10.3390/ph18030411
APA Style
Kette, S., Reccardini, N., Salton, F., Confalonieri, P., Andrisano, A., Chianese, M., De Nes, A., Maggisano, M., Galantino, A., Nicolosi, S., Mari, M., Salotti, A., Angoni, D., Chernovsky, M., Hughes, M., Confalonieri, M., Mondini, L., & Ruaro, B.
(2025). The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis. Pharmaceuticals, 18(3), 411.
https://doi.org/10.3390/ph18030411
